Candel Therapeutics (CADL) said Wednesday it released final survival data from its phase 2a trial of CAN-2409 in advanced non-small cell lung cancer patients resistant to immune checkpoint inhibitor treatment.

The study demonstrated positive results, with a median overall survival of 24.5 months in the evaluable patients, surpassing standard care outcomes.

Key findings include a median overall survival of 21.5 months in patients with progressive disease despite ICI therapy, compared to 9.8 to 11.8 months with standard docetaxel chemotherapy. Additionally, 37% of patients survived beyond two years after receiving CAN-2409, while 69% showed regression in uninjected tumors, demonstrating an abscopal effect. Non-squamous NSCLC patients had the best outcomes, with a median overall survival of 25.4 months, the company said.

Throughout the long-term study, CAN-2409 maintained a strong safety profile and was well-tolerated by patients, Candel Therapeutics said.

Candel shares rose 2.5% in after-hours trading.